Login to Your Account



Zynerba rallies from epilepsy setback on fragile X findings with CBD agent

By Marie Powers
News Editor

Thursday, September 28, 2017

History did not repeat itself for cannabinoid developer Zynerba Pharmaceuticals Inc. A month after shares lost more than half their value following a primary endpoint miss in the phase II study of lead candidate cannabidiol (CBD) gel ZYN-002, Zynerba rebounded in a big way.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription